Forsys Metals Corp. (FOSYF) 0.1680 $FOSYF Forsys

New Post Public Reply Private Reply Replies (0) Message Board

May 19, 2015 at 3:39 AM

Forsys Metals Corp. (FOSYF) 0.1680 $FOSYF

Forsys Announces Annual and General Meeting Voting Results
Marketwired - Wed May 06, 6:01AM CDT
Forsys Metals Corp. (TSX: FSY)(FRANKFURT: F2T)(NAMIBIAN: FSY) ("Forsys" or the "Company"

is pleased to announce today that in connection with the annual and general meeting of the Company's shareholders held in Toronto on May 5, 2015 (the 'Meeting'

and in accordance with section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, the following voting results were obtained.
FSY.TO: 0.22 (+0.02)

Forsys Releases Feasibility Study Results for Norasa Uranium Project in Namibia
Marketwired - Wed Mar 18, 6:31AM CDT
Forsys Metals Corp. (TSX: FSY)(FRANKFURT: F2T)(NAMIBIAN: FSY) ("Forsys" or the "Company"

is pleased to announce the results of a Feasibility Study(1) ("FS"

for its wholly-owned Norasa Uranium Project ("Norasa"

located in the Erongo region of Namibia. The FS completed by engineering consultants, Amec Foster Wheeler together with reliance on other experts in the fields of mining and environment and Company Qualified Persons, has confirmed the robustness and economics of Norasa. All amounts are in US currency. A copy of the FS can be found under Forsys' filings on SEDAR.
FSY.TO: 0.22 (+0.02)

Forsys Provides Norasa Uranium Project Feasibility Study Update
Marketwired - Wed Nov 26, 6:01AM CST
Forsys Metals Corp. (TSX: FSY) (FRANKFURT: F2T) (NAMIBIAN: FSY) ("Forsys" or the "Company"

is pleased to announce the completion of a metallurgical report by SGS South Africa (Pty) Ltd ("SGS"

. This study is a major component of the Company's Norasa Uranium Project Feasibility Study ("FS"

being prepared by AMEC Foster Wheeler and slated for completion in Q1 2015.
FSY.TO: 0.22 (+0.02)

Forsys Closes $2.4 Million Private Placement
Marketwired - Wed Oct 29, 7:34AM CDT
Forsys Metals Corp. (TSX: FSY)(FRANKFURT: F2T)(NAMIBIAN: FSY) ("Forsys" or the "Company"

today reported that it has closed its previously announced non-brokered private placement by issuing 9,420,000 units at $0.25 per unit for gross proceeds of $2,355,000 (CDN).
FSY.TO: 0.22 (+0.02)

Forsys Provides Update on Private Placement & Progress on the Norasa Feasibility Study
Marketwired - Thu Oct 09, 4:01PM CDT
Forsys Metals Corp. (TSX: FSY)(FRANKFURT: F2T)(NAMIBIAN: FSY) ("Forsys" or the "Company"

is pleased to announce that the terms of its previously announced (see August 8, 2014 news release) non-brokered private placement (the "Private Placement"

have changed. The Company has received binding commitments from subscribers to purchase a total of 9,420,000 units of the Company ("Units"

at $0.25 per Unit, for total gross proceeds of $2,355,000.
FSY.TO: 0.22 (+0.02)

Canoe Mining Appoints Parnham as President and CEO
CNW Group - Thu Oct 02, 7:45AM CDT
Canoe Mining Ventures Corp. (TSXV: CLV) ("Canoe"

is pleased to announce the appointment of Mr. Duane Parnham as President and CEO of Canoe effective immediately. Mr. Parnham has had a long successful career working in the resource sector and gained a thorough understanding of the Canoe assets in his current position as Executive Chairman of Giyani Gold Corp., Canoe's largest shareholder.
CLV.VN: 0.045 (+0.005), ANA.VN: 0.005 (unch)

Affiliate of Leo Fund Managers Announces Acquisition of Common Shares and Warrants of Forsys Metals Corp.
CNW Group - Tue Sep 23, 6:57PM CDT
Leonardo Trust ("Leonardo"

, an affiliate of Leo Fund Managers Limited, announced today that its wholly-owned subsidiary, Leonardo Global Trading Ltd., has entered into an agreement with Forsys Metals Corp. ("Forsys"

to subscribe for 7,200,000 units ("Units"

of Forsys on a private placement basis at a price of $0.25 per Unit for an aggregate purchase price of $1,800,000 (the "Private Placement"

. Each Unit consists of one Class A Common Share (each a "Common Share"

and one half of one Common Share purchase warrant (each, a "Warrant"

that entitles the holder to acquire a new Common Share in Forsys at a price of $0.35 for a period of two years from the date of issue. The Private Placement is subject to the approval of the Toronto Stock Exchange.

Forsys Metals Announces Non-Brokered Private Placement
Marketwire - Fri Aug 08, 11:01AM CDT
Forsys Metals Corp. (TSX: FSY)(FRANKFURT: F2T)(NAMIBIAN: FSY) ("Forsys" or the "Company"

is pleased to announce that it intends to raise up to C$3.2m in gross proceeds by way of a non-brokered private placement of up to 10,000,000 units ("the Units"

in the Company at a subscription price of $0.32 per Unit.
FSY.TO: 0.22 (+0.02)

Forsys Metals Initiates Feasibility Study for Norasa Uranium Project
Marketwire - Mon Jul 07, 7:20AM CDT
Forsys Metals Corp. (TSX: FSY) (FRANKFURT: F2T) (NAMBIAN: FSY) ("Forsys" or the "Company"

is pleased to announce that it has engaged AMEC to commence a Feasibility Study ("FS"

for its 100% owned and permitted Norasa Uranium Project ("Norasa"

located in Namibia. AMEC is a leading international engineering and project management firm with prior involvement in the development of NI 43-101 Technical Reports for Norasa. SGS South Africa has also been appointed to complete additional metallurgical studies, which will include pilot plant testwork. The FS will also include the input of other specialist consultants for certain aspects of the study. These areas include an update of the pit designs, tailings handling systems and bulk water and power supply. Some technical aspects have already been completed to a level suitable for the FS including the resource model and pit geotechnical designs.
FSY.TO: 0.22 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Tennessee's Bold Lung Cancer Trial Signals Innovation

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Miranda Lambert Lights Up Red Kettle Campaign

By Logan Wright Updated Oct 25, 2026 Category News Views 227

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...